



Corporate Presentation

Fall 2020

NASDAQ : BSGM



Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

BioSig Technologies Positioned for Success



- **Multi-billion dollar** electrophysiology (EP) market
 - Demand driven by high prevalence of arrhythmia
 - Procedures more efficacious than drugs, predicated on ability to analyze clean cardiac signals
- **Differentiated value proposition** and impact to the patient
 - Current standard of care negatively affected by signal “noise” and artifacts
 - PURE EP™ System offers a cleaner signal and potentially superior patient outcomes
- **ViralClear subsidiary** testing an anti-viral therapy for COVID-19
 - Broad-spectrum anti-viral now in Phase II clinical trial in 10 sites around the U.S.
 - In vitro studies shown 98% reduction in viral load
- **Robust** commercialization strategy – FDA cleared technology
 - Supported by world-renowned key opinion leaders
 - Strategy led by a dynamic, experienced team
- **Strong** intellectual property portfolio
 - 31 allowed / issued worldwide design and utility patents

Seasoned Management Team, Possessing the Necessary Skillset and Knowledge to Drive Commercialization



Kenneth L. Londoner, MBA
Founder, Chairman, CEO, Director
NeuroClear Technologies; ViralClear Pharmaceuticals;
Endicott Management Partners; J & W Seligman & Co.



Steve Chaussy, CPA
CFO
NeuroClear Technologies; Liberski Inc; Anna & Co; Penske
Automotive; Ford Hogg and Cobbe



Natasha Drapeau
Executive Vice President
NeuroClear Technologies; Alliance for Advancing Bioelectronic
Medicine; Institute of Directors, UK; IG Group Plc, UK



Andy Ballou
Vice President, Investor Relations
Janney Montgomery Scott; RBC Capital Markets



Todd Wiltshire
Senior Vice President, Corporate Development
Fidelity Investments; Credit Agricole; UBS; Morgan Stanley



Barry Keenan, Ph.D, MBA, PMP
Vice President, Engineering
Medtronic; Nexeon MedSystems; Alfred Mann Institute for Biomedical
Engineering; Alfred Mann Foundation for Scientific Research



John Kowalski
Vice President, Sales
Biosense Webster (Johnson & Johnson)



Julie Stephenson, BSN, MBA
Vice President, Clinical Affairs
Medtronic; Boston Scientific; Guidant Corporation



Manasi Patwardhan
Director of Strategic Planning Verily Life Sciences,
Boston Scientific - Neuromodulation; Medtronic



Olivier Chaudoir
Senior Director, Marketing
Biosense Webster; DePuy Synthes



Defining the Market Opportunity

Global Growth in EP Devices:

\$4.5B in 2017, projected to reach \$7.4B in 2022


10.4% growth rate

Global Growth

in Complex Cardiac Ablation
Procedures:

440,629 in 2017 to 830,390 in 2022

13.5% growth rate




Data source: 2018 MD&D report


Electrophysiology Market Overview

Consistent, long-term growth is driven by demographic trends and clinical evidence (ablation vs. drug therapy)

Key Market Players



Global Market Share for Catheter Ablation Devices



Source: B. C. C. Research (2018, November). Atrial Fibrillation: Technologies and Global Markets

As Hospitals Resume Elective Procedures, Should they Prioritize Electrophysiology During COVID-19?


EP procedures are clinically urgent

- Delaying procedure increases stroke risk and worsens outcomes

EP procedures are revenue generating

- CV surgery and invasive cardiology have the highest net annual revenue compared to all other service lines

Median Revenues Per Case For Ablation and Select EP Procedures



Reimbursement rates continue to increase


- From 2019 to 2020 ablations and LAAO (DRG 274) had a reimbursement rate increase of 8.8%

CMS Reimbursement Changes From FY 2019 to FY 2020

Procedure	Reimbursement Rate Change
Inpatient	
All inpatient services	2.5%
Ablations and LAAO (DRG 274)	8.8%
Pacemaker implant (DRG 244)	0.9%
ICD implant (DRG 227)	0.9%
Outpatient	
All outpatient services	2.6%
Ablations (APC 5213)	6.3%
Pacemaker implant (APC 5223)	3.8%
ICD implant (APC 5232)	5.3%

PURE EP™ Developed Through Collaboration with Leading Centers

Relationships at leading, high-volume centers create traction for PURE EP™ in the market




Unique Collaboration with Mayo Clinic

- 10-year strategic agreement
 - Collaboration on technology development
 - Joint IP filings
 - Licensing opportunities
 - Mayo Clinic has invested capital in the development of the PURE EP™ System
- Phase 2 clinical trial support for ViralClear Pharmaceuticals, Inc.
- First PURE EP™ System installed at Mayo Clinic in Florida in January 2020



Our First FDA-Cleared Product - PURE EP™ System: Addressing Unmet Clinical Need of More Reliable ECG Signals

PURE EP™ System provides **innovative technology** that fulfills unmet clinical needs while benefitting patients, physicians, and payors



- ✓ Signal processing platform designed to reveal the full range of cardiac signals and to provide electrophysiologists with signal clarity during catheter ablation procedures and related studies
- ✓ Refines signal clarity by reducing signal “noise” to allow clinicians to deliver therapy during the procedures with higher precision
- ✓ Allows surgeons to potentially work more accurately, decreasing the probability of a repeat procedure, and thus increasing the procedure’s safety and efficacy profile
- ✓ Reduced procedure time creates an economic incentive for hospitals and allows physicians to see more patients over a given time period
- ✓ Improved safety profile potentially creates a more favorable payor environment for reimbursement

First Successful Clinical Use of PURE EP™

"With the use of the PURE EP™ System I was able to identify cardiac signals which were previously undetectable to me. I believe that the PURE EP™ System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes."


Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX. February 20, 2019

"We found that the clarity of the signals made a great difference in the confidence with which we could continue applying ablation energy to an abnormal pathway that was in the region of the normal conduction system; BioSig's technology allowed us to see a clear signal from the normal conduction pathway during ablation that was obscured by noise on our standard recordings."

Prof. John M. Miller, M.D., Indiana University School of Medicine. May 06, 2019




Our Clinical Path



Our Recent PURE EP™ Study - ESC 2020

- A blinded, independent analysis confirmed that the PURE EP™ system's signals are preferred to conventional sources
- In 35.5% of samples, the reviewers selected PURE EP™ data because "more signal components were visible"
- PURE EP™ System produces reliable and high-quality signals when compared to the standard of care systems





Presenting PURE EP™ at Leading Conferences in Order to Boost Awareness and Physician Support

25th Annual International
AF SYMPOSIUM | 2020

AFIB SYMPOSIUM 2020
JAN 23-25
PLACE: Washington, DC



Spotlight Session: Innovation in EP
Dr. Andrea Natale



Booth:
Technology Demonstration



Presentation: (i) Clinical and Economic Evidence Generation
(ii) Technical Data Collection and Abstracts



EPLive
2020

EP LIVE 2020
DEC 2020
PLACE: Austin, TX
St David's Medical Center

Formally Invited
Live Cases
New Approaches and
Technologies in EP

**VENTRICULAR
ARRHYTHMIAS:**
Pathophysiology & Therapy

VT Symposium
OCT 9-10
PLACE: New York City

Customer **Engagement**
Technology Demonstration
focused on **VT optimization**



Technology Video
• THE CHALLENGE TODAY
• OUR SOLUTION

Key Milestones

2020

- ✓ Targeted commercial release of PURE EP™ System
- ✓ Clinical data publication and new evidence-based trials
- ✓ Obtain top line Phase 2 clinical data for merimepodib
- ✓ Initiate Phase 3 pivotal trial for COVID-19
- ✓ Develop new product pipeline to complement PURE EP™
- ✓ File further IP

2021

- ✓ Accelerate commercialization of PURE EP™ in U.S.
- ✓ Deliver Phase 3 results for COVID-19 therapy
- ✓ File further IP, advance R&D in bioelectronic medicine
- ✓ Clinical data publication and new evidence-based trials
- ✓ Gain European regulatory approval for PURE EP™
- ✓ Explore strategic partnerships and licensing opportunities



MASSACHUSETTS
GENERAL HOSPITAL

Strong IP Strategy, Supported by Experts

27 allowed/issued worldwide design and utility patents, which cover various features of the PURE EP™ System's display screens and graphical user interface for enhanced visualization of biomedical signals



Differentiated combination of hardware and software is supported by strong IP and serves as the main competitive advantage over competing systems

Sherpa Technology Group and Sterne Kessler Goldstein & Fox are effectively developing patent and IP strategy

Conducted a thorough Landscape Review to understand ability to successfully file patents

BioSig is an exclusive licensee of Mayo Clinic to several patents and applications covering software features of PURE EP™ and additional complementary technologies







All patents and applications are assigned or exclusively licensed to the company

COVID-19 Asset Developed by Subsidiary, ViralClear Pharmaceuticals

- Merimepodib, lead compound, currently in Phase 2 clinical trial for COVID-19
 - Broad-spectrum, orally administered anti-viral previously tested in other indications
 - Commenced Phase II clinical trial in June 2020 at Mayo Clinic under the leadership of Andrew D. Badley, M.D., Enterprise Chair of the COVID-19 Task Force
 - Trial size expanded from 40 to 80, with focus on patients requiring non-invasive ventilation/high flow oxygen devices
 - Top line data expected in Q420
- Exceptionally strong, expert management team
 - Dr. Jerome B. Zeldis (CMO) - former Chief Medical Officer of Celgene
 - Steve King (COO) - extensive small molecule outsourcing drug development expertise from development through to commercial launch
- Strong scientific rationale and data support treatment for COVID-19
 - *In vitro* studies shown 98% reduction in viral load
 - Viral load was reduced to undetectable levels in combination with remdesivir
 - First *in vitro* data published in online peer-reviewed journal
- Clean safety profile
 - 437 patients previously treated in other indications



EP Sector M&A Activity

Company	Proof of Concept	Prototype	Clinical Data	CE Mark	FDA	Sales	Acquirer/ Investor	Valuation
BioSig Technologies Formed 2009	•	•	•		•			\$148.00 million Oct 02, 2020
EPD Solutions Formed 2014	•	•	•	•		•	PHILIPS	\$563 million June 2018
HeartWare	•	•	•	•	•	•		\$1.1 Billion June 2016
Hansen Medical	•	•	•	•	•	•	AURIS Surgical Robotics	\$80 million April 2016
nContact Formed 2005	•	•	•	•			AtriCure	\$149 million Oct 2015
CardioInsight Formed 2006	•	•	•	•	•	•		\$272 million June 2015
Topera Medical Formed 2010	•	•	•	•	•			\$350 million Dec 2014
Endosense SA Formed 2003	•	•	•	•		•		\$331 million Aug 2013
Bard EP Division of CR Bard	•	•	•	•	•	•		\$275 million Nov 2013
Rhythmia Medical Formed 2004	•	•	•					\$410 million Oct 2012

Business Model Summary

Highlights:

- PURE EP™ System expected to generate revenue beginning in H2 2020
- Scaling up organization through increasing salesforce and extending relationships with world-class healthcare institutions
- Robust US-based supply chain
- Additional product pipeline covering novel therapies for autonomic nervous system disease
- Enrolling patients into Phase 2 trial for COVID-19 in some of the most impacted states – *data expected Q420*
- Potential Phase 3 trial commencement, Q420

BSGM Snapshot:

Key Company Data	(10/02/20)
Recent price:	\$4.82
52-week range:	\$2.36 - \$12.43
Primary shares i/o:	29.8 million
Public float:	21.9 million
Market cap:	\$148.00 million
Average volume (1 month):	952,579 shares

Board of Directors

	Kenneth L. Londoner, MBA			
	Andrew Filler, JD			
	Donald E. Foley, MBA			
	Patrick J. Gallagher, MBA, CFA			
	Samuel E. Navarro			
	Jeffrey F. O'Donnell, Sr.			
	Martha Pease			
	David Weild IV, MBA			
	Jerry Zeldis, M.D., Ph.D			
	Anthony Zook			